Search research articles
Contact Us
Filters
Showing results (41-50 of 64) with videos related to
Page
of 7
Sort By:
Journal of Pharmaceutical and Biomedical Analysis
|
May 31, 2022
Validation of an LC-MS/MS method for the quantification IOA-289 in human plasma and its application in a first-in-human clinical trial
M Mameli, J Franchi, G Calusi, et al.
International Journal of Oncology
|
October 2, 2014
A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer
Allen Cohn, Michael M Lahn, Kristen E Williams, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
April 10, 2019
Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma
Sandrine Faivre, Armando Santoro, Robin K Kelley, et al.
International Journal of Clinical Pharmacology and Therapeutics
|
December 24, 2005
Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors
U Eismann, O Oberschmidt, M Ehnert, et al.
Investigational New Drugs
|
March 7, 2020
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma
Antje Wick, Annick Desjardins, Cristina Suarez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2009
A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer
B Glimelius, M Lahn, S Gawande, et al.
Plos One
|
June 17, 2021
Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Gianluigi Giannelli, Armando Santoro, Robin K Kelley, et al.
Clinical and Translational Gastroenterology
|
July 12, 2019
A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
R K Kelley, E Gane, E Assenat, et al.
Plos One
|
March 27, 2020
Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Gianluigi Giannelli, Armando Santoro, Robin K Kelley, et al.
Drug Design, Development and Therapy
|
August 27, 2015
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
Stephan Herbertz, J Scott Sawyer, Anja J Stauber, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 64) with videos related to
Sort By:
Page
of 7
Journal of Pharmaceutical and Biomedical Analysis
|
May 31, 2022
Validation of an LC-MS/MS method for the quantification IOA-289 in human plasma and its application in a first-in-human clinical trial
M Mameli, J Franchi, G Calusi, et al.
International Journal of Oncology
|
October 2, 2014
A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer
Allen Cohn, Michael M Lahn, Kristen E Williams, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
April 10, 2019
Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma
Sandrine Faivre, Armando Santoro, Robin K Kelley, et al.
International Journal of Clinical Pharmacology and Therapeutics
|
December 24, 2005
Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors
U Eismann, O Oberschmidt, M Ehnert, et al.
Investigational New Drugs
|
March 7, 2020
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma
Antje Wick, Annick Desjardins, Cristina Suarez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2009
A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer
B Glimelius, M Lahn, S Gawande, et al.
Plos One
|
June 17, 2021
Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Gianluigi Giannelli, Armando Santoro, Robin K Kelley, et al.
Clinical and Translational Gastroenterology
|
July 12, 2019
A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
R K Kelley, E Gane, E Assenat, et al.
Plos One
|
March 27, 2020
Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Gianluigi Giannelli, Armando Santoro, Robin K Kelley, et al.
Drug Design, Development and Therapy
|
August 27, 2015
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
Stephan Herbertz, J Scott Sawyer, Anja J Stauber, et al.
Page
of 7